The test will complement the already existing Cue molecular COVID-19 test and will be compatible with the Cue Health Monitoring System and the Cue Health Mobile Application, according to a Jan. 6 press release.
“An omicron-specific test will assist clinicians in providing patients better treatment options and containment strategies at the time of a positive diagnosis,” Cue CEO Ayub Khattak said in the press release.
Since 2018, HHS’ BARDA has funded Cue Health projects like over-the-counter influenza diagnostic cartridges for its monitoring system and its portable COVID-19 test.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.